special offer

Generic Name: Berotralstat for Hereditary Angioedema (berotralstat)

Berotralstat for Hereditary Angioedema Reviews

Orladeyo (berotralstat) "Used danocrine 200mg every day for about 30 years, had less than 2-4 attacks annually. Switched to Orladeyo 150mg once a day, 15 weeks ago, experience consistently 1 attack every 6-7 day which I control by 1 dosage Berinert. Benefit with Orladeyo is the significant longer onset time of an attack, never been a rush to stop the attack, usually have 12 or more hours after I sense the attack and resolve it with Berinert. Icatibant alone, never resolves the attack, it pauses it for about 5-6 hours and then proceeds. Experienced 3 times of extreme heartburn the first 8 weeks, felt like burning sensation around the heart area."


Orladeyo (berotralstat) "Orladeyo has been a very good option for me and has been doing as good of a job as expected against my severe, extremely stubborn heart attacks. I'm trying my best to give this medicine at least the full year to prove its worth. Let me say I'm getting more and more discouraged after yet another case of the worst stomach pains of my life after taking my daily dose. I had vomiting for almost 12 hours, the most serve stomach pains I've ever had. Now here I am on day 2 and I'm afraid to drink, eat, etc because my stomach is still sensitive, cramping, and having spasms and I'm so afraid to feel that worst pain again. I want to love this pill I do but I'm neutral right now."


Orladeyo (berotralstat) "Reduced attacks significantly. Very happy with the drug so far and its oral."

More about berotralstat

  • Check interactions
  • Compare alternatives
  • Side effects
  • Dosage information
  • During pregnancy
  • Drug class: hereditary angioedema agents
  • Breastfeeding
  • En español

Patient resources

  • Berotralstat drug information
  • Berotralstat (Advanced Reading)

Other brands

Orladeyo

Professional resources

  • Berotralstat monograph

Other brands

Orladeyo

Related treatment guides

  • Hereditary Angioedema